Report: Autopsy found Cincinnati Bearcats offensive lineman Jeremiah Kelly had heart condition
ESPN reported on Tuesday that Jeremiah Kelly, an early enrollee who took part in spring practices with the Bearcats, had 'cardiac hypertrophy,' a thickening of the heart muscles. He was found unresponsive at his residence on April 22.
'The Bearcats football family is heartbroken by the sudden loss of this outstanding young man,' coach Scott Satterfield said in April. 'In the short time Jeremiah has spent with our team, he has made a real impact, both on the field and in our locker room. My prayers are with the Kelly family and those who had the pleasure of knowing Jeremiah.'
A freshman from Avon, Ohio, Kelly was a 6-foot-3, 320-pound offensive lineman who helped Avon High School to a 16-0 record and a state championship in 2024.
___
AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Sleep Doctors Have Surprisingly Good News If You Like To Fall Asleep Watching TV
Let's just say that many sleep hygiene tips are far from tempting. For example, there's waking up at the same time every day (no thanks, I like to sleep in on the weekends!). There's also avoiding caffeine close to bedtime (what about my emotional-support Diet Coke?). The good news is, another key example has recently been debunked (to a certain extent). It's watching — or even more so, listening — to a TV show before bed. 'Many people ask me if falling asleep while watching TV is alright,' said Dr. Emma Lin, a board-certified pulmonologist, sleep medicine specialist and co-founder of 'The reality is, it is just right for some individuals.' Typically, we hear it's important to avoid screens before bed because they emit blue light, which can suppress the production of melatonin and disrupt our circadian rhythms (or our bodies' 'internal clocks'). This can make our bodies think it's time to be awake. But according to sleep doctors, it's not that simple. Ahead, they explain how watching TV before bed can actually be beneficial, and how to do it right. Watching TV Can Become Part Of Your Bedtime Routine One more piece of sleep advice you've probably heard, for context: to have a bedtime routine. That might look like showering, taking your medication, brushing your teeth and hopping under the sheets. A routine helps with sleep because, over time, your brain associates the two. For some people, TV is a part of that process. 'Their brain learns to associate it with falling asleep, so trying to sleep without it brings on anxiety,' said Dr. Chester Wu, the medical advisor at Rise Science who's double board-certified in psychiatry and sleep medicine. 'It's not that TV is helping them sleep — it's that it's become a part of their wind-down habit.' Having TV as a part of your routine is even more 'OK' if it's paired with other healthy sleep practices. 'I've often recommended that watching TV before bed (when paired with other tailored and effective sleep strategies) can be a helpful part of a nightly routine,' said Dr. Michael Gradisar, the head of sleep science at Sleep Cycle. TV Screens May Not Be The Problem We Thought Blue light, blue light, blue light … as much as we hear about it, it's not necessarily the thing that keeps you awake. 'While blue light from phones or screens is often blamed for poor sleep, my research has shown that the biggest disrupter is actually delaying bedtime,' Gradisar said. With that said, watching TV may be a better option compared to scrolling on your phone. 'Of the screen-based activities people engage in before bed, watching TV is the least disruptive,' Gradisar said. 'TV is a passive device compared to phones.' Additionally, the light may not be as bright, and therefore as problematic, as we thought. Lin said if the screen isn't super bright, and the content isn't disturbing, 'there's a negligible effect.' Gradisar agreed. He pointed to a 2024 study in Sleep Medicine Reviews that found light emitted from screens is not intense enough to disrupt sleep. TV Time Can Reduce Nighttime Anxiety Feel more anxious at night? Perhaps you can't stop thinking about all you have to get done tomorrow, or you keep having 'cringe attacks'? If so, you're not alone: According to survey findings published by the American Psychological Association, 43% of people have lain awake at night due to stress. Watching TV can get your mind off your worries, allowing your brain to slow down and drift off. But again, it just comes down to timing. 'Watching TV or listening to a podcast as a wind-down routine can be perfectly fine, especially if it helps reduce nighttime overthinking, as long as it doesn't cut into the number of hours of rest you get,' Gradisar said. Lin agreed, with an additional point. 'If what you watch is calm, something you've watched before, it can wind down your brain,' she said. 'That gets you asleep sooner.' TV Isn't Necessarily The No. 1 Answer To Your Sleep Woes, Though However, it's essential to note that other studies have found blue light (or just bright light) from screens to be harmful. Wu said that a TV screen in a darkened room — the latter of which is ideal for sleep — creates more circadian disruption than the same screen in a bright environment. There's also the psychological or sociological piece to consider: We stay up watching TV because, well, we want to stay up watching TV. 'This includes staying up later than planned or engaging in revenge bedtime procrastination, which is when you try to reclaim personal time late at night,' Wu said. And that's a good example of another one of his points: Your sleep may be disrupted more than you realize. 'Even if you don't feel wired after watching TV, it may still impact your sleep quality in subtle ways,' Wu said. (Hello, 'junk sleep.') Follow These Best Practices From Doctors If you're going to fall asleep to a TV show, Lin and Wu suggested following this advice: Set a sleep timer so the TV turns off after 30 to 60 minutes Angle the screen away so it's not directly shining on you Stick to familiar, low-drama, soothing shows Turn down the volume Use night mode or dim your screen Don't wear headphones — sound coming directly into your ears keeps your brain more awake Try blue light-blocking glasses Practice other healthy sleep habits (such as sleeping in a cool, dark room; exercising; avoiding caffeine; and keeping naps to around 20 minutes) Set boundaries around screen time and bedtime Go to bed at the same time every night The bottom line: Listen to your body and watch its patterns. 'If you sleep with [the] TV on, track whether you feel more or less rested on certain nights, or notice differences in how easily you wake up,' Wu said. From there, stick with what works. If you're used to sleeping without a TV or a screen, that may be your best bet. If TV is a part of your nighttime routine, consider following those earlier best practices to ensure it's as least harmful as possible. Related... Hot Sleeper? These 14 Genius Products Can Help You Get Better Rest If You Struggle To Fall Asleep, You Might Have This Specific Type Of Insomnia 'Orthosomnia' Might Be Ruining Your Sleep. Here's What You Should Know.
Yahoo
6 minutes ago
- Yahoo
Latest Jim Harbaugh experiment could have a major impact on Justin Herbert's season
For Jim Harbaugh, all competitors are welcome. But along the interior of the Chargers' offensive line — an Achilles' heel amid last year's success, too often leaving Justin Herbert running for his life — the battle isn't over who will start, but where. Like last season, Zion Johnson and Bradley Bozeman are locked in as starters. What remains undecided is whether Johnson will line up at guard or center, and vice versa for Bozeman, as the two continue what Harbaugh called 'not really a competition, but a competition to get our best combination.' In training camp, the two are rotating between spots each practice, continuing a trial that began during organized team activities. Read more: Rashawn Slater agrees to four-year, $114-million deal with Chargers For Johnson, the move goes beyond uncharted territory. He has never taken a competitive snap at center at any level, aside from a handful of Senior Bowl reps in 2022. Though the Chargers never mentioned playing him at center when they drafted him, Johnson says he always saw it as a real possibility given his size and defensive awareness. But the organization didn't seriously explore the idea until the end of last season, when they started having him cross-train to see how he'd fare. 'It was pretty early in the offseason,' Johnson said of the pitch. 'I want to help the team in any way possible, whether that's left guard and now having experience at center. ... However they see fit, I'm willing to plug in.' Saturday marked Johnson's first full-padded practice at center, where he progressed in both pass and run protection but also struggled, missing stunts and committing a false start. What the staff sees, Harbaugh says, is elite athleticism: quick first steps, an ability to climb to the second level — traits that hint at a real upside if Johnson can adjust. For now, Johnson's biggest hurdle is the lack of consistent reps. Without them, it's hard to build comfort with the nuances beyond blocking — from pre-snap reads and protection calls to, most important, snapping. 'Not having played center before, every rep is valuable,' Johnson said. '[I'm] trying to get the reps in and fit in where I can. ... Getting snaps before practice, getting snaps after, getting snaps in my room.' Johnson's position change is also a chance for him to prove worthy of a long-term contract. The Chargers declined the former first-round pick's fifth-year option, making this the final year of his rookie contract. That decision was one of several the Chargers have made to spur improvement on the offensive line. On Sunday, the Chargers signed two-time Pro Bowl left tackle Rashawn Slater to a four-year, $114-million extension. With Slater and right tackle Joe Alt solidifying the edges, the line's interior remains the primary concern. Mekhi Becton was the solution at right guard. The addition of Andre James briefly appeared to signal a change at center, but he hasn't taken any first-team reps and was omitted by Harbaugh when discussing competition, largely because of Bozeman's two-year, $6.5-million contract with the team. Upon his return, the front office made it clear to Bozeman that he would not only compete but also try his hand at both positions. 'From the jump, that's what we were going to be doing, we were going to be rotating and playing different positions,' Bozeman said. 'I knew I was competing to start. Always been a competitor, never backed down from a challenge.' For Bozeman, the challenge lies in re-acclimating to guard — a less daunting task for the soon-to-be 31-year-old, even though he hasn't played guard in a game in nearly five years. 'I've mixed in a little bit of guard through the last couple training camps,' Bozeman said. 'Went back and watched some old film, picked up some old tips for myself, so it's like riding a bike.' Offensive coordinator Greg Roman called the experiment 'way too early to tell how things will shake out,' but said the transition has been 'pretty seamless" so far, with the much more experienced Bozeman mentoring Johnson — despite the competition. But in just over a month, the Chargers will face a decision. They can either proceed with the experiment after a full preseason of reps — featuring an aging center making his first regular-season start at guard in years, and a guard making his first-ever regular-season start at center. Read more: With Chargers back in San Diego, players hope to win back their traditional fan base Or they could revert to last year's pairing, where both started all 17 games but struggled mightily, especially in pass protection. Bozeman and Johnson each ranked near the bottom of the league in hits, sacks and pressures allowed, according to Pro Football Focus. Even so, the staff believes the cross-training will boost the offensive line's overall versatility, regardless of how the competition plays out. With the Hall of Fame Game against the Lions in Canton, Ohio, days away, Harbaugh remains undecided on whether the starting unit will play in the preseason opener — a decision he said will be made later this week. If Johnson starts at center, he'll also continue taking snaps at guard, and Bozeman will do the same, with Harbaugh saying that's 'the best thing for our team and our offensive line. We're going to continue to cultivate that.' Get the best, most interesting and strangest stories of the day from the L.A. sports scene and beyond from our newsletter The Sports Report. This story originally appeared in Los Angeles Times.
Yahoo
6 minutes ago
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
